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Aims and objectives: Despite the successes in managing drug-susceptible TB, drug-resistant
(DR) tuberculosis is a major challenge to the effectiveness of National Tuberculosis Program
in Armenia, placing the country in the list of 18 high-burden countries for MDR-TB in the
WHO European Region. Estimated burden of MDR-TB in 2012 was 9.4 (7–12) and 43 (38–49)
among retreatment TB cases. A total of 92 laboratory confirmed cases had been reported to
the WHO (57 new and 35 previously treated) out of 511 cases tested for MDR-TB. GenoType
MTBDRsl is a new molecular kit designed for rapid identification of the resistance to the
second-line antituberculosis drugs with a single strip. The aim of this study was to identify
the mutation that confers resistance to ethambutol (EMB) in Mycobacterium tuberculosis in
comparison with the phenotypic drug susceptibility test (DST). Ethambutol is used in
M/XDR-TB regimens only if it is susceptible by DST results.
Methods: A set of 173 drug resistances TB isolates during 2011 and 2012 period, being either
acid fast bacterium positive or negative but culture positive resistant to isoniazid, rifampin,
or both according to the GenoType MTBDR plus assay were consecutively tested, using the
GenoType MTBDRsl (MTBDR plus version 1.0 and MTBDRsl version 2.0 Hain Lifescience,
Nehren). embB gene analysis and the resultswere compared to phenotypic EMB testing (DST).
The DNA preparation method used as described recommended by the manufacturer.
Results: Genotypic analysis identified mutations at codon 306 of the embB gene in 20.8%
(36/173) andmiss band of wild type in 12.71% (22/173) of the resistant isolates in comparison
to only 14.45% (25/173) of those thatwerephenotypically resistant to EMBbyDSTMGIT liquid
media. Mutation locus were identified in embBMUT1B and embBMUT1A 8.67% (15/173) and
12.13% (21/173), simultaneously.
Phenotypic retesting inMGIT demonstrated that 45 (306 of the embB gene andmiss band of
wild type together) genotypically resistant isolates were phenotypically resistant to EMB.
This implies that 58.62% (33/58) of EMB resistancehadbeenphenotypicallymissed by routine
laboratory procedures. EMB resistance was closely linked to multidrug resistance (MDR);
70.69% (41/58) of the EMB-resistant isolates were resistant to both isoniazid and rifampicin.
Conclusion: Implementation of more accurate diagnosis of EMB resistance may enhance
patient management in Armenia, as standardized treatment of MDR-TB with second-line
drugs is currently dependent on the outcome of the EMB resistance test.
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